FDA-approved CAR T-cell Therapies | UPMC Hillman

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses a patients own genetically modified T cells to find and kill cancer. UPMC Hillman Cancer Center currently offers two types of FDA-approved CAR T-cell therapy.

UPMC Hillman Cancer Center was one of the first in the United States certified to provide ABECMA (idecabtagene vicleucel) for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an antidCD38 monoclonal antibody.

Hillman was the first of 10 centers in the United States to offer BREYANZI (lisocabtagene maraleucel), an FDA-approved CAR T-cell therapy for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including:

UPMC Hillman Cancer Center is the first in western Pennsylvania to provide TECARTUSTM (brexucabtagene autoleucel), an FDA-approved CAR T-cell therapy for patients with relapsed or refractory mantle cell lymphoma.

UPMC Hillman Cancer Center is part of the network of certified treatment centers providing KYMRIAHTM(tisagenlecleucel), an FDA-approved CAR T-cell therapy for:

UPMC Hillman Cancer Center is the first center in western Pennsylvania providing YESCARTATM (axicabtagene ciloleucel), the first FDA-approved CAR T-cell therapy for adult patients with certain types of B-cell lymphoma.

The FDA has approved this treatment for patients with the following conditions that have either not responded to or have relapsed following two or more lines of systemic therapy:

Patients will undergo an extensive evaluation to determine their eligibility for this highly specialized treatment. To learn more, please call 1-833-UPMC-CART.

Patients who are approved for CAR T-cell therapy will undergo the following treatment process:

To refer a patient for evaluation for one of these clinical trials, please call 1-833-876-2227 (1-833-UPMC-CART).

If you think you might be a candidate for one of these clinical trials, please call 1-833-876-2227 (1-833-UPMC-CART).

More here:
FDA-approved CAR T-cell Therapies | UPMC Hillman